Lundbeck gears up as Alzheimer's agitation approval looks attainable

Anticipating a US market authorization for a treatment candidate for Alzheimer’s agitation, the Danish pharmaceutical firm is getting things in order – all due to the summer’s compelling phase III evidence.

Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH

Over the summer, Danish pharmaceutical firm Lundbeck and partner Otsuka Pharmaceutical received some very positive phase III data for their co-developed candidate, brexpiprazole, as a potential treatment for Alzheimer’s agitation.

Lundbeck CEO Deborah Dunsire tells MedWatch that preparations have now begun for if and when a market authorization is secured for the substance, sold under brand-name Rexulti for major depressive disorder and schizophrenia.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs